Allogenic coming fast but at least they are making an allogenic "Yescarta" with trial launch 2H 2020..
They do seem to be dragging their feet but with all the Yescarta trials going on, they are learning a lot of real world results about how CART works in humans.
I thought they are also altering manufacturing process to change percentages of cd4 vs cd8 cells as well as with and without steroids.
Should be a lot of good CART education there before launching allogenic.
For those that think CART has "failed", slow adoption of a new 1st gen product is just the beginning..
Figure GILD CART will hit $1B next year and $2B in 2021 before the other CART programs and label expansions really kick in..